Citigroup increases its rating on Vanguard Health Systems VHS from Neutral to Buy (both High Risk) and raises its price target from $11 to $12.
Citigroup comments, "We are upgrading VHS from Neutral (2H) to Buy (1H) as we assume a more positive view of the near-term (30day) risk/reward around the Supreme Court's healthcare reform ruling. We are reducing the regulatory risk adjustment in our current target price methodology. Our new target price of $12 represents ~23x '13 P/E (ex-HCIT) and 6.1x EV/EBITDA without any effect of the healthcare reform law."
VHS closed at $7.96 on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in